In the short-term BLRX does not seem to be like a good trade. Ive been struggling with this stock lately. Some of my other trades have been from awe-SOME-stock-s which are working out pretty well.
People must understand this - it has deep value. You are getting a cancer treatment going into phase 3 and company valued less than $100 million. It will go to $2-$3 before Nov. or before if they announce some interim analysis
BioLineRx: At Around $1, This Sleeper Biotech Stock Is A Strong Buy
BioLineRx might be one of the best biotech values in the stock market, as it has a promising pipeline, a cash-rich balance sheet and a low burn rate. Don't be p
something is up ...very heavy volume ...
If they get rid of Phil, the share price would rise by at least .20
Advisory board and CMO are running the trials, BLRX self proclaimed, they don't need cash until 2020
What the hell is Phil doing?
Will close at .79
.06 From breaking a new record low Phil has got to go!
Nothing is keeping this POS from tanking to .25 This efin management team is looking at a possibility of another failed trial
If Novartis bails, BLRX is toast
nothing happens after shareholders meeting
This moron of of a CEO is going to get BLRX delisted
You suk Phil,K girl was better and she suked
Been holding BLRX for sometime but it seems nothing can make this stock move up; still awaiting patiently....urghhh
You suk Phil
IGXT (MC $46 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .GLTA
2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $46 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .Load up guys before she the MEGA news hit the wire and thank me later .GL
MarketCap $46 Million Cash ~$12 Million (including convertible debt) =cash untill 2021+ Price: 0.70
NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July NDA resubmission for Rizaport (migraine) in early Q3 Partnership for Tadalafil in 2H 2017
IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.
Phil the efin moron CEO will have us trading in the pink sheets by years end. K girl was horrible, this f-in moron is a waste of a load.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.6 In other words, the correlation coefficient of the other stock